These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 26510912)

  • 1. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
    Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
    Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy.
    Zhao J; Dean DC; Hornicek FJ; Yu X; Duan Z
    Cancer Lett; 2020 Apr; 474():158-167. PubMed ID: 31987920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
    Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
    Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.
    Ross JS; Badve S; Wang K; Sheehan CE; Boguniewicz AB; Otto GA; Yelensky R; Lipson D; Ali S; Morosini D; Chliemlecki J; Elvin JA; Miller VA; Stephens PJ
    Arch Pathol Lab Med; 2015 May; 139(5):642-9. PubMed ID: 25927147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma.
    Carlson JA; Caldeira Xavier JC; Tarasen A; Sheehan CE; Otto G; Miller VA; Stephens PJ; Elvin JA; Vergilio JA; Suh J; Gay LM; Ross JS
    Am J Dermatopathol; 2017 Jan; 39(1):1-13. PubMed ID: 28045747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma.
    Xiao X; Wang W; Zhang H; Gao P; Fan B; Huang C; Fu J; Chen G; Shi L; Zhu H; Li X; Li J; Fan H; Wu Z; Guo Z; Hu Y; Wu S; Yu X; Xu C; Wang Z
    Tumour Biol; 2015 Apr; 36(4):2427-35. PubMed ID: 25431261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study.
    Lee H; El Jabbour T; Ainechi S; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon SH; Ali SM; Schrock A; Fabrizio D; Frampton G; Nazeer T; Miller VA; Stephens PJ; Ross JS
    Hum Pathol; 2017 Dec; 70():84-91. PubMed ID: 29079173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic landscape of salivary gland tumors.
    Kato S; Elkin SK; Schwaederle M; Tomson BN; Helsten T; Carter JL; Kurzrock R
    Oncotarget; 2015 Sep; 6(28):25631-45. PubMed ID: 26247885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer.
    Kim HS; Lee H; Shin SJ; Beom SH; Jung M; Bae S; Lee EY; Park KH; Choi YY; Son T; Kim HI; Cheong JH; Hyung WJ; Park JC; Shin SK; Lee SK; Lee YC; Koom WS; Lim JS; Chung HC; Noh SH; Rha SY; Kim H; Paik S
    Oncotarget; 2017 Jun; 8(24):38389-38398. PubMed ID: 28418920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials.
    Friedlander ML; Russell K; Millis S; Gatalica Z; Bender R; Voss A
    Int J Gynecol Cancer; 2016 May; 26(4):648-54. PubMed ID: 26937756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
    Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong DS; Kurzrock R
    Cancer Res; 2016 Jul; 76(13):3690-701. PubMed ID: 27197177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-b as Involved in the Pathogenesis of Osteosarcoma.
    Yang R; Piperdi S; Zhang Y; Zhu Z; Neophytou N; Hoang BH; Mason G; Geller D; Dorfman H; Meyers PA; Healey JH; Phinney DG; Gorlick R
    Clin Orthop Relat Res; 2016 Jan; 474(1):178-89. PubMed ID: 26463566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RUNX2 (6p21.1) amplification in osteosarcoma.
    Gupta S; Ito T; Alex D; Vanderbilt CM; Chang JC; Islamdoust N; Zhang Y; Nafa K; Healey J; Ladanyi M; Hameed MR
    Hum Pathol; 2019 Dec; 94():23-28. PubMed ID: 31669178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged response to sorafenib in a patient with refractory metastatic osteosarcoma and a somatic PDGFRA D846V mutation.
    Armstrong AE; Walterhouse DO; Leavey PJ; Reichek J; Walz AL
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27493. PubMed ID: 30318721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of the response to chemotherapy in conventional osteosarcomas: predictive value of HSD17B10 and IFITM2.
    Salas S; Jézéquel P; Campion L; Deville JL; Chibon F; Bartoli C; Gentet JC; Charbonnel C; Gouraud W; Voutsinos-Porche B; Brouchet A; Duffaud F; Figarella-Branger D; Bouvier C
    Int J Cancer; 2009 Aug; 125(4):851-60. PubMed ID: 19449377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
    Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
    PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
    Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
    Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mutation characteristics of osteosarcoma: a single center study of 64 cases using next-generation sequencing].
    Gao DL; Dong RF; Liu WF; Gong LH; Xu HR; Niu XH; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):370-375. PubMed ID: 36973198
    [No Abstract]   [Full Text] [Related]  

  • 20. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.
    Ross JS; Ali SM; Wang K; Palmer G; Yelensky R; Lipson D; Miller VA; Zajchowski D; Shawver LK; Stephens PJ
    Gynecol Oncol; 2013 Sep; 130(3):554-9. PubMed ID: 23791828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.